» Articles » PMID: 35813747

A Guide for Managing Patients with Stage I NSCLC: Deciding Between Lobectomy, Segmentectomy, Wedge, SBRT and Ablation-part 2: Systematic Review of Evidence Regarding Resection Extent in Generally Healthy Patients

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2022 Jul 11
PMID 35813747
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clinical decision-making for patients with stage I lung cancer is complex. It involves multiple options (lobectomy, segmentectomy, wedge, stereotactic body radiotherapy, thermal ablation), weighing multiple outcomes (e.g., short-, intermediate-, long-term) and multiple aspects of each (e.g., magnitude of a difference, the degree of confidence in the evidence, and the applicability to the patient and setting at hand). A structure is needed to summarize the relevant evidence for an individual patient and to identify which outcomes have the greatest impact on the decision-making.

Methods: A PubMed systematic review from 2000-2021 of outcomes after lobectomy, segmentectomy and wedge resection in generally healthy patients is the focus of this paper. Evidence was abstracted from randomized trials and non-randomized comparisons with at least some adjustment for confounders. The analysis involved careful assessment, including characteristics of patients, settings, residual confounding etc. to expose degrees of uncertainty and applicability to individual patients. Evidence is summarized that provides an at-a-glance overall impression as well as the ability to delve into layers of details of the patients, settings and treatments involved.

Results: In healthy patients there is no short-term benefit to sublobar resection lobectomy in randomized and non-randomized comparisons. A detriment in long-term outcomes is demonstrated by adjusted non-randomized comparisons, more marked for wedge than segmentectomy. Quality-of-life data is confounded by the use of video-assisted approaches; evidence suggests the approach has more impact than the resection extent. Differences in pulmonary function tests by resection extent are not clinically meaningful in healthy patients, especially for multi-segmentectomy lobectomy. The margin distance is associated with the risk of recurrence.

Conclusions: A systematic, comprehensive summary of evidence regarding resection extent in healthy patients with attention to aspects of applicability, uncertainty and effect modifiers provides a foundation on which to build a framework for individualized clinical decision-making.

Citing Articles

Effectiveness and safety of segmentectomy vs. wedge resection for the treatment of patients with operable non‑small cell lung cancer: A meta‑analysis and systematic review.

Xiu J, Wang S, Wang X, Xu W, Hu Y, Hua Y Oncol Lett. 2024; 28(1):336.

PMID: 38846430 PMC: 11153982. DOI: 10.3892/ol.2024.14469.


Minimally invasive segmentectomy and lobectomy for peripheral stage IA1-2 non-small-cell lung cancer: a case-matched cohort study from a UK Centre.

Brunelli A, Rushwan A, Stefanou D, Drosos P, Chaudhuri N, Milton R Interdiscip Cardiovasc Thorac Surg. 2023; 37(6).

PMID: 38092061 PMC: 10746861. DOI: 10.1093/icvts/ivad204.


CyberKnife stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study.

Oudin V, Salleron J, Marchesi V, Peiffert D, Khadige M, Faivre J J Thorac Dis. 2023; 15(9):4636-4647.

PMID: 37868838 PMC: 10586995. DOI: 10.21037/jtd-22-1245.


Sublobar resection versus lobectomy for stage IA non-small-cell lung cancer ≤ 2 cm: a systematic review and patient-level meta-analysis.

Fong K, Chan Y, Chia C, Agasthian T, Lee P Updates Surg. 2023; 75(8):2343-2354.

PMID: 37563486 DOI: 10.1007/s13304-023-01627-z.


Segmentectomy is the Surgical Procedure of Choice for Peripheral Early-Stage Non-small Cell Lung Cancer (Most Likely!).

Brunelli A Ann Surg Oncol. 2023; 30(8):4553-4555.

PMID: 37138169 DOI: 10.1245/s10434-023-13579-0.


References
1.
Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J . Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. J Clin Oncol. 2016; 34(26):3175-82. DOI: 10.1200/JCO.2015.64.6729. View

2.
Anami K, Horie J, Hirayama Y, Yamashita N, Ito K . Changes in exercise tolerance and quality of life are unrelated in lung cancer survivors who undergo video-assisted thoracic surgery. J Phys Ther Sci. 2018; 30(3):467-473. PMC: 5857460. DOI: 10.1589/jpts.30.467. View

3.
Bedetti B, Bertolaccini L, Rocco R, Schmidt J, Solli P, Scarci M . Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2017; 9(6):1615-1623. PMC: 5506148. DOI: 10.21037/jtd.2017.05.79. View

4.
Bendixen M, Jorgensen O, Kronborg C, Andersen C, Licht P . Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016; 17(6):836-844. DOI: 10.1016/S1470-2045(16)00173-X. View

5.
Gu Z, Wang H, Mao T, Ji C, Xiang Y, Zhu Y . Pulmonary function changes after different extent of pulmonary resection under video-assisted thoracic surgery. J Thorac Dis. 2018; 10(4):2331-2337. PMC: 5949488. DOI: 10.21037/jtd.2018.03.163. View